Figure 2.

Sustained Increase in Myelopoiesis upon β-Glucan Administration

(A–F) WT mice were injected with β-glucan or PBS, and BM analysis was performed after 7 days.

(A) LSK, MPP and LT-HSC cell numbers in the BM of mice on day 7 after administration of PBS or β-glucan (n = 6 mice per group).

(B) Frequency of MPP subpopulations in the LSK cells 7 days after β-glucan or PBS administration (n = 5 mice per group).

(C) Frequency of CD41⁺ LT-HSCs (in total LT-HSCs) on day 7 after the administration of PBS or β-glucan (n = 5 mice per group).

(D) Representative FACS plots for the identification of MyP subpopulations.

(E and F) GMP cell numbers (E) and frequency within the MyP pool of GMPs (Lin⁻c-Kit⁺Sca1⁻CD16/32⁺CD34⁺) and CMPs (Lin⁻c-Kit⁺Sca1⁻CD16/32⁻CD34⁺) (F) in the BM of mice on day 7 after the administration of PBS or β-glucan (n = 6 mice per group).

(G–I) WT mice were injected with β-glucan or PBS, and BM analysis was performed after 28 days.

(G) LSK and LT-HSC cell numbers (n = 5 mice per group).

(H and I) Frequency of MPP4 cells in total BM cells (H) and GMP cell numbers in the BM (I) of mice on day 28 after the administration of PBS or β-glucan (n = 5 mice per group).

(J and K) Transplantation.

(J) LT-HSCs (CD45.2⁺) were sorted 28 days after β-glucan or PBS administration and transplanted to lethally irradiated SJL/BL6 (CD45.1⁺) mice. CD45.1⁺ BM cells were co-transplanted in order to ensure the survival of recipients.

(K) Lineage output of donor LT-HSCs (CD45.2⁺) in peripheral blood of recipients at week 12 post-transplant (n = 10 recipient mice per group).

Data are presented as mean ± SEM. ^∗p < 0.05; ^∗∗p < 0.01; ^∗∗∗p < 0.001; ^∗∗∗∗p < 0.0001.

See also Figure S2.